STATE HOUSE — Rep. Joseph M. McNamara (D-Dist. 19, Warwick, Cranston) proposed bill, 2020-H 8078, would subsidize rare disease treatments through an insurer-contribution fueled reinsurance program.
If passed, the bill would establish the Rhode Island Rare Disease Medication Accessibility, Affordability and Reinsurance Act, creating the rare disease medication reinsurance program.
“Patients with rare fatal or debilitating diseases have been given new hope because of technological advances in medical research,” said McNamara, “But the cost of those treatments can be exceedingly high, and the rareness of the conditions can compound those costs, leading to financial trouble for individuals, employers and insurers. Sometimes these organizations have no choice but to drop coverage of these expensive treatments all together. This bill would facilitate coverage and fair financing by allocating the costs for those medications as broadly as possible.”
The program would be administered by the Secretary of Health and Human Services based on recommendations from a 15-member advisory council. The bill would authorize the Executive Office of Health and Human Services to administer a fund to pay for a portion of the coverage by collecting funds from payers as broadly as possible, based on estimated costs, and distributing the funds to any insurer, plan, or program that paid for a patient to be treated with one of the identified drugs.
The bill would not create any new financial liability for the state.
Earlier this year, the House of Representatives passed McNamara’s bill (2020-H 7266) allowing chronically ill patients to obtain experimental drugs that have not yet been federally approved but which may be in the final stages of FDA testing.
Author: Rob Borkowski
Rob has worked as reporter and editor for several publications, including The Kent County Daily Times and Coventry Courier, before working for Gatehouse in MA then moving home with Patch Media. Now he's publisher and editor of WarwickPost.com. Contact him at [email protected] with tips, press releases, advertising inquiries, and concerns.
This is a test
